Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

943
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
943
Steps in Outbreak Investigation01:18

Steps in Outbreak Investigation

786
In the ever-evolving field of public health, statistical analysis serves as a cornerstone for understanding and managing disease outbreaks. By leveraging various statistical tools, health professionals can predict potential outbreaks, analyze ongoing situations, and devise effective responses to mitigate impact. For that to happen, there are a few possible stages of the analysis:
786
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

758
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
758
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

400
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
400
Therapeutic Drug Monitoring: Drug Analysis Methods01:26

Therapeutic Drug Monitoring: Drug Analysis Methods

327
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
327
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

957
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
957

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Burnout, depression, and medication errors among family physicians.

Scientific reports·2025
Same author

Prevalence of tuberculosis infection among patients undergoing regular hemodialysis: a multicenter study in Egypt.

Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace·2025
Same author

Incidence and determinants of extrapulmonary tuberculosis in Egypt: a retrospective cohort study.

Scientific reports·2025
Same author

Unveiling NLR pathway signatures: EP300 and CPN60 markers integrated with clinical data and machine learning for precision NASH diagnosis.

Cytokine·2025
Same author

Enhanced prediction of hemolytic activity in antimicrobial peptides using deep learning-based sequence analysis.

BMC bioinformatics·2024
Same author

Exploring the prevalence of chlamydial and gonorrheal infections in pregnant women: a multicenter study in Egypt.

BMC public health·2024

Related Experiment Video

Updated: Apr 19, 2026

Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples
08:54

Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples

Published on: May 19, 2020

8.4K

Temporal Knowledge Discovery in Drug-Resistant Tuberculosis: A Decade-Long Machine Learning Analysis From Egyptian

Hanan Elsayed1, Fayek Elkhwsky2, Wagdy Amin3

  • 1PhD Graduate, Biomedical Informatics and Medical Statistics, Medical Research Institute, Alexandria University, Alexandria, Egypt.

International Journal of Medical Informatics
|April 17, 2026
PubMed
Summary

Machine learning models effectively predict drug-resistant tuberculosis (DR-TB) using clinical and treatment history data. This approach aids in early DR-TB detection and optimizes treatment strategies in high-burden regions.

Keywords:
Drug susceptibility testingDrug-resistant tuberculosisEgyptLongitudinal predictorsMachine learningRandom ForestSHAP

More Related Videos

Matrix-based DNA Extraction for Targeted Next-Generation Sequencing on Decontaminated Sputum Samples
06:07

Matrix-based DNA Extraction for Targeted Next-Generation Sequencing on Decontaminated Sputum Samples

Published on: June 6, 2025

1.5K
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

8.4K

Related Experiment Videos

Last Updated: Apr 19, 2026

Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples
08:54

Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples

Published on: May 19, 2020

8.4K
Matrix-based DNA Extraction for Targeted Next-Generation Sequencing on Decontaminated Sputum Samples
06:07

Matrix-based DNA Extraction for Targeted Next-Generation Sequencing on Decontaminated Sputum Samples

Published on: June 6, 2025

1.5K
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

8.4K

Area of Science:

  • Medical Informatics
  • Computational Biology
  • Epidemiology

Background:

  • Tuberculosis (TB) remains a global health challenge, exacerbated by multidrug-resistant TB (MDR-TB).
  • Traditional diagnostic methods for TB are often slow and lack precision.
  • There is a critical need for advanced predictive tools to combat TB and MDR-TB.

Purpose of the Study:

  • To develop and validate machine learning (ML) models for identifying risk factors of drug-resistant tuberculosis (DR-TB).
  • To analyze clinical and longitudinal treatment-history data from Egyptian patients (2012-2022).
  • To differentiate DR-TB from drug-susceptible TB (DS-TB) using AI-driven insights.

Main Methods:

  • A retrospective case-control study involving 1,462 patients across three Egyptian respiratory hospitals.
  • Data included demographics, clinical history, lifestyle factors, and drug resistance patterns (pDST, Xpert MTB/RIF).
  • Four ML models (Random Forest, XGBoost, KNN, Neural Networks) were trained and validated using SHAP for feature selection and cross-validation.

Main Results:

  • The Random Forest model achieved the highest performance with 94.54% accuracy and 94.46% ROC-AUC.
  • XGBoost also demonstrated strong performance with 93.17% accuracy.
  • Key predictors included prior first-line drug use, patient category, treatment history, geographic region, and radiological findings.

Conclusions:

  • Machine learning models demonstrate high efficacy in distinguishing DR-TB from DS-TB using longitudinal clinical data.
  • Integrating treatment history and geographic risk factors with AI provides a robust framework for early DR-TB prediction.
  • This AI-driven approach can optimize treatment initiation and resource allocation in TB high-burden settings.